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390 | Nanoscale, 2013, 5, 390–400Factors aﬀecting T cell responses induced by fully
synthetic glyco-gold-nanoparticles†
Silvia Fallarini,a Tiziana Paoletti,a Carolina Orsi Battaglini,a Paolo Ronchi,b Luigi Lay,b
Renato Bonomi,c Satadru Jha,c Fabrizio Mancin,c Paolo Scrimin*c
and Grazia Lombardi*c
We have synthesized and characterized nearlymonodisperse and highly pure gold nanoparticles (2 and 5 nm)
coated with non-immunoactive mono- and disaccharides, modelled after the capsular polysaccharide of
serogroup A of the Neisseria meningitidis bacterium. We have used them to test their ability to induce
immune cell responses as a consequence of their multivalency. The results indicate that they are indeed
immunoactive and that immunoactivity is strongly dependent on size, and larger, 5 nm nanoparticles
perform far better than smaller, 2 nm ones. Immune response (activation of macrophages) initiates with
the whole nanoparticle recognition by the surface of antigen-presenting cells, independent of the
saccharide oligomerization (or charge) on the nanoparticle surface. The induction of T cell proliferation
and the increase of IL-2 levels, a consequence of the expression of MHC II involved in antigen
presentation, require the presence of a disaccharide on the nanoparticle, not just a monosaccharide. A
possible explanation is that, at this stage, the saccharides are detached from the gold surface. These results
may provide leads for designing new saccharide-based, nanoparticle-conjugate vaccines.Introduction
Monolayer-protected gold nanoparticles (Au-NPs) share with
several nanosystems (liposomes, dendrimers, for instance) the
property of multivalency1,2 since they present a collection of
functional groups on their periphery. It is a widely accepted
paradigm that multivalent systems show enhanced binding
ability against multivalent counterparts.1,3 This is the case for
systems governing cell–cell, protein–protein, and protein–cell
interactions, for instance.4 Multivalency of Au-NPs has been
exploited for many applications5,6 spanning, inter alia, enzyme
mimicry,7–9 protein sensing and recognition,10–12 and gene
regulation.13 For drug or gene delivery, the ability to release
their payload, once internalized into cells,14,15 in a process
mediated by cytoplasmic thiol compounds is an advantage of
Au-NPs over other polymeric nanosystems where the cargo is
covalently, and hence very strongly, bound to the polymer. Oneniversity of “Piemonte Orientale Amedeo
ly. E-mail: lombardi@pharm.unipmn.it;
4
emistry, CISI, ISTM-CNR, University of
ly
NR, University of Padova, Via Marzolo 1,
unipd.it; Fax: +39 049 8275829; Tel: +39
SI) available: Fig. S1–S10 mentioned in
systems, nanoparticle characterization,
r32338aof the major problems related to the use of Au-NPs for
biomedical applications is the fact that immune cells in the
bloodstream and in tissues have the ability to entrap and
eliminate Au-NPs.16–19 A nanoparticle's interaction with plasma
proteins (opsonins) and blood components (via hemolysis,
thrombogenicity and complement activation) may inuence
uptake and clearance and hence potentially aﬀect distribution
and delivery to the intended target sites. The conventional way
to overcome this problem is to make Au-NPs stealthy to the
immune system, typically by functionalization on their surface
with polyethers.20,21
In addition to their primary role in pathogen clearance,
blood components like the complement system also promote
humoral and cell-mediated immunity. Local activation of
complement by nanoparticles administered via subcutaneous
and intradermal routes may indeed benet vaccine eﬃcacy. In
this paper we address the question of the interaction of
saccharide-functionalized Au-NPs in vitro with blood compo-
nents like monocytes with the aim to evidence their ability to
induce immune responses and the factors (size, saccharide
oligomerization) inuencing it. Successful systems may nd
applications as synthetic vaccines. The design of new vaccines
requires the mimicry of key pathogen features like size, shape
and surface molecule organization without, of course, the
ability to cause diseases.22 For these reasons nanosystems like
dendrimers and polymers have been used for this purpose.
Properly functionalized gold nanoparticles23,24 appear to be
suitable choices for antigens because antigen processing isThis journal is ª The Royal Society of Chemistry 2013
‡ For the sake of clarity we refer to the gold core to identify the size of the
nanoparticles throughout the paper.
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View Article Onlinefacilitated if antigens are particulate and have a repetitive
surface organization, which increases phagocytosis and the
ability, as said above, to activate complement and recruit other
molecules of the innate humoral immune system. Peptide-
functionalized Au-NPs have shown the ability to enhance
immune responses in cells,25,26 and gold nanoparticles bearing
tumor-associated glycopeptide antigens have recently been
reported as promising potential cancer vaccines.27
We have recently shown28 that Au-NPs functionalized with
oligosaccharides (Glyco-Au-NPs) designed to mimic the poly-
saccharide capsule that coats serogroup A of the Neisseria
meningitidis bacterium29 (MenA) bind very strongly to poly-
clonal human antibodies against MenA. At the same nominal
concentration of saccharides the nanoparticles showed a more
than three orders of magnitude higher binding aﬃnity than
their counterparts not bound to the gold cluster: a remarkable
result, fully consistent with the multivalent nature of the
system. Our data showed also that the strength of the interac-
tion with the antibodies was not dependent on the oligomeri-
zation of the saccharide used for the passivation of the gold
cluster as mono-, di- and tri-saccharide-functionalized Au-NPs
performed quite similarly. In contrast, the aﬃnity constants of
nanoparticle-unbound saccharides were oligomerization-
dependent with the trisaccharide performing best. This
suggests that the antibody when interacting with the Au-NPs
can hardly diﬀerentiate a surface made up by a mono-, di- or tri-
saccharide. Synthetically this is quite relevant because a
monosaccharide is much more accessible than an oligomer,
even short as a trisaccharide.
A complex cascade of events is required for inducing
immune responses. These events include adaptive events that
take place on the surface of antigen-presenting cells (APCs),
which display foreign antigens coupled with MHC to a T cell
receptor complex for eﬀective T cell priming and B/T cell acti-
vation. APCs collaborate also with the innate system by cyto-
kines, which steers the diﬀerentiation of T helper (Th) cells into
Th1 or Th2 subsets.30 Accordingly, in addressing the ability of
our Glyco-Au-NPs to elicit immune cell responses, we have
evaluated: (a) the activation of APCs; (b) the induction of
eﬀector functions in the same cells; and (c) the ability to stim-
ulate T cells. The role of the size and of the oligomerization of
the saccharide present on the surface of the nanoparticles in the
diﬀerent processes studied has been addressed by considering
Glyco-Au-NPs of two diﬀerent sizes (2 and 5 nm core diameter)
passivated with thiols functionalized with a mono- and a
disaccharide. Liposome-, polymer- or dendrimer-based vaccines
are typically of a size of at least 10 nm.22 We used Glyco-Au-NPs
with a maximum overall diameter of ca. 9 nm corresponding to
a gold core of 5 nm because a 5.5 nm diameter of the gold core is
considered as the threshold limit to allow renal clearance in
gold-based nanoparticles31 and, hence, to avoid accumulation
of the metal in the organism: a critical issue for possible in vivo
applications. Thus our size limit was the result of considering
both renal clearance and maximization of APC interactions for
possible future vaccine development. In spite of the fact that the
two sizes studied are not much diﬀerent, the results indicate
that the behavior of the Glyco-Au-NP is quite diverse. OurThis journal is ª The Royal Society of Chemistry 2013selected pathogen has been the Neisseria meningitidis bacterium
to compare our results with the previous ones28 concerning
polyclonal antibody aﬃnities but also for the high relevance of
this bacterium that causes the highest incidence of epidemics
in Saharan and sub-Saharan countries of Africa (the so-called
“African meningitis belt”).32 Furthermore, bacterial meningitis
remains a global problem worldwide, accounting for an esti-
mated annual number of 1.2 million cases with at least 5–10%
case fatality in industrialized countries and 20% in the devel-
oping world.33 It is thus not surprising that the scientic
interest in new approaches for eﬀective vaccine development
remains very high.34–36Results and discussion
Synthesis and characterization of Au nanoparticles
We have prepared following our protocol,37 which is a modi-
cation adapted for water-soluble Au-NPs of the two-phase Brust
synthesis38 (Fig. 1), 2 and 5 nm nanoparticles‡ functionalized
with monomeric and dimeric saccharides29 (Glyco-Au-NP 1–2
and 3–4, respectively). Since incorporation of a triethylenglycol
(TEG) unit in the monolayer provides to Au-NPs water solubility,
prevents nanoparticle aggregation that occurs at the ionic
strength of the experiments with cells, and non-specic inter-
actions with biomolecules,20 TEG-Au-NPs 5 and 6 were used as
Au-NP controls in all experiments, while saccharides 8 and 9
were used as monovalent comparison molecules. Glyco-Au-NP 7
is equivalent to Glyco-Au-NP 4 as for dimension and saccharide
composition. It diﬀers from 4 for the presence of 5% of uo-
rescein as a uorescent tag and was prepared to monitor cell
internalization of the nanoparticles. In disaccharide 9 and that
present in gold nanoparticles 3 and 4, the native phosphodiester
bridge connecting the glycosidic units of MenA has been
substituted with a phosphonate29 as a hydrolytically more stable
moiety to prevent early degradation with loss of the Glyco-Au-NPs
properties. The Au-NPs were analyzed, for their size, by trans-
mission electron microscopy (TEM) and dynamic light scattering
(DLS) (see Table 1 for relevant physical properties) and, for the
purity of the monolayer, by 1H-NMR and thermogravimetry (see
ESI†). While TEM provides the size of the gold core, DLS gives the
hydrodynamic diameter of the nanoparticle (gold core and
surrounding monolayer). DLS is particularly sensitive to the
presence of aggregated nanoparticles because of the strong
increase of scattered intensity with size. All our samples showed
no evidence of aggregation, thus suggesting that the passivation
with the saccharides makes them very soluble and not prone to
interacting reciprocally. The thiol/particle ratio that gives infor-
mation on the multivalency of the Glyco-Au-NPs has been
obtained from the thermogravimetric analysis and size data as
reported.41 Glyco-Au-NPs with a monolayer composed of a
monosaccharide (1 and 2) are neutral, while those composed of a
disaccharide (3 and 4) are anionic, as proven by the respective Z
potentials (Table 1).Nanoscale, 2013, 5, 390–400 | 391
Fig. 1 Gold nanoparticles and thiolated saccharides described in this work.
Table 1 Physical properties of gold nanoparticles described in this work
Au-NP
Size, nm
Thiols/particlec Z potential, mVTEMa DLSb
1 1.8  0.5 6.2  1.8 80 +3  4
2 4.9  0.9 9.3  2.2 480 +4  4
3 1.8  0.4 6.5  2.0 70 29  3
4 5.0  0.8 9.6  2.1 450 30  4
5 1.9  0.4 n.d. n.d. n.d.
6 4.8  1.0 n.d. n.d. n.d.
a Diameter of the gold core. b Hydrodynamic diameter of the entire
nanoparticle. c Mean value estimated from the thermogravimetric
analysis and the size of the gold core (see ref. 39 for details).
§ The concentrations indicated in the case of the nanoparticles refer to the
organic component. The Au-NP concentration can be derived by dividing these
numbers by the number of ligands present on the monolayer as reported in
Table 1.
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View Article OnlineMacrophage activation
Preliminarily, we ruled out the possibility that immune cell
responses were due to the presence of endotoxin contamina-
tions, such as lypopolysaccharide (LPS), introduced into the
system through chemicals, materials, or equipment. Limulus
amebocyte lysate endochrome assays were performed in four
diﬀerent batches of each compound and the concentration of
LPS was measured. LPS concentrations were always below the
value of 0.01 ng ml1, suﬃcient to stimulate immune cell
responses,42 suggesting that the compounds under testing were
LPS-free and biologically evaluable (data not shown). In addi-
tion, to exclude the possibility that the compounds are cyto-
toxic, cell viability was evaluated by a Trypan blue exclusion test
aer 24 h cell exposure to each compound. All compounds
showed no toxicity at all concentrations tested (data not shown).
Macrophages are potent immune cells that provide an
immediate response against pathogens and may act as APCs to
activate adaptive immune responses. Exposure to pathogens
can induce a rapid activation of macrophages, which stop
proliferation and acquire eﬀector cell functions.43392 | Nanoscale, 2013, 5, 390–400We, thus, analyzed in vitro the eﬀects of nanoparticles 1–6
and saccharides 8 and 9 on macrophage proliferation using
RAW 264.7 cells, a widely used cellular model that accurately
replicates APC biology, such as antigen uptake, processing, and
presentation.44 Cells were rendered quiescent prior to each
assay by 18 h serum deprivation. Aer 24 h exposure to
increasing concentrations (1  102 to 1  102 mM)§ of each
compound, cell proliferation was signicantly inhibited (55 
1% over compound-untreated cells as controls) only by 5 nm
Glyco-Au-NPs 2 and 4 at a 1  102 mM concentration (Fig. 2). To
demonstrate that the inhibition of macrophage proliferation is
specic and not related to a reduction in cell viability, the Try-
pan blue exclusion test was performed at the end of cell expo-
sure to each compound. The results indicate that the observed
decrease in cell proliferation is not due to cytotoxicity as cell
viability remains >95%. Apoptosis and necrosis were also
analyzed under epiuorescence microscopy in cells treated with
1  102 mM Glyco-Au-NPs 1–4 for 24 h. Cells treated with the
non-conjugated saccharides 8 and 9 or the TEG-functionalized
Au-NPs 5 and 6 devoid of the saccharides were used as a
comparison. Actinomicyn D, a cytotoxic inducer of apoptosis,45
was used as a positive control. None of the tested Glyco-Au-NPs
signicantly aﬀected cell death, indicating that the inhibition of
cell proliferation occurs through a specic blockage of the cell
cycle progression (ESI, Fig. S6†).
This result suggests that the conjugation to Au-NPs confers
to the saccharides the ability to activate macrophages and that
this property is dependent on the Au-NP size, with 5 nm
nanoparticles giving comparable results to those obtained when
the polysaccharide bacterium capsule (MenA) is used as aThis journal is ª The Royal Society of Chemistry 2013
Fig. 2 Concentration–response curves of the tested compounds onmacrophage
proliferation (RAW 264.7 cells) expressed as the percentage over compound-
untreated cells (CTRL). Compound identiﬁcation number as in Fig. 1. The data
represent means  SEM of ﬁve experiments run in triplicate. *P < 0.05; **P < 0.01
versus compound-untreated cells (CTRL).
Table 2 Eﬀect of the Au-unbound thiols 8 and 9 and of the diﬀerent gold
nanoparticles (1 102 mM) on RAW 264.7 cell morphology andMHC II expression
Sample Dendritic-like cells, % MHC II expression, %
CTRL 6  0.5 5.3
MenA 73  3 29.8
1 37  2 18.4
2 70  2 35.5
3 32  1.5 9.0
4 68  2 29.3
5 6  0.8 5.9
6 4  0.3 6.8
8 10  1.1 5.7
9 9  1.5 6.8
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View Article Onlinenatural antigen. Moreover, there is little diﬀerence in the
activity of 5 nm Glyco-Au-NPs, regardless of whether they are
functionalized with a monomeric or a dimeric saccharide
(compare 2 vs. 4). Thus, macrophage activation is dependent on
size, but very little on oligomerization (or charge) of the
saccharide on the Au-NP surface.
Since the blockage of macrophage cycle progression corre-
lates with a cell phenotype diﬀerentiation from macrophage- to
dendritic-like cells, we then studied the eﬀects of the nano-
particles on RAW 264.7 cell morphology. As shown in Fig. 3,
native cells (CTRL) had a macrophage-like morphology with
small nuclei and nely granulated cytoplasm. Cells appeared
elongated with two short cytoplasmic processes. Amorphological
transformation of RAW 264.7 cells from macrophage-like cells
into dendritic-like cells was clearly observed aer cell treatment
with Glyco-Au-NPs (1  102 mM). Dendritic morphology was
characterized by multiple prominent cytoplasmic processes.
Glyco-Au-NP-treated cells acquired larger nuclei, prominent
nucleoli, and increased cytoplasmic granularities. ThisFig. 3 Glyco-Au-NPs induced macrophage phenotype diﬀerentiation. The pictur
nanoparticles it refers to the organic component) on macrophage (RAW 264.7 cells)
2.5-fold magniﬁcation.
This journal is ª The Royal Society of Chemistry 2013morphological transformation is particularly evident in cells
treated with 5 nm Glyco-Au-NPs, as the percentage of dendritic-
like cells was almost twice that observed with the smaller (2 nm)
Glyco-Au-NPs (Table 2).
At the same concentration (1 102 mM) Glyco-Au-NPs elicited
similar responses to that observed with MenA. No signicant
eﬀects were observed in the cells treated either with the non-
conjugated saccharides 8 and 9 or the TEG-functionalized Au-
NPs 5 and 6. This result indicates that the functionalization, and
not just the Au-NPs per se, is at the origin of the observed eﬀects.
The blockage of macrophage proliferation, together with the
acquisition of a dendritic-like phenotype, clearly indicates that
the Glyco-Au-NPs are immunoactive.
The next step was to investigate whether Glyco-Au-NPs acti-
vate eﬀector functions in the same cells. Fig. 4 and 5 show the
eﬀects induced by each compound on the production of typical
pro-inammatory mediators (e.g. ROS and TNF-a). The data
demonstrate that, aer processing Glyco-Au-NPs 1–4 as anti-
genic molecules, macrophages become active APCs (although to
diﬀerent extents) that attract responder cells to the site of the
inammation and start adaptive immune cell responses.
Themembrane expression of class IImajor histocompatibility
complex molecules (MHC II), which represents the rst marker
of a mature APC, was then examined by ow cytometry in RAWes show the eﬀects of the tested compounds (1  102 mM, in the case of the
morphology after 24 h exposure (scale bar ¼ 30 nm). The inset for 4 represents a
Nanoscale, 2013, 5, 390–400 | 393
Fig. 4 Eﬀects of the diﬀerent compounds on intracellular reactive oxygen
species (ROS) production: (a) monosaccharide-functionalized Glyco-Au-NPs 1 and
2 and unbound monosaccharide 8; (b) disaccharide-functionalized Glyco-Au-NPs
3 and 4 and unbound disaccharide 9. The percentage of ROS was measured by
incubating the cells with the ﬂuorescent probe DCFH-DA. RAW 264.7 cells were
seeded (0.5  105 cells per well) in 24-well plates and treated with increasing
concentrations (102 to 102 mM) of each compound for 1 h. TEG-functionalized
Au-NPs 5 and 6 were used as Au-NP controls while compound-untreated cells
(CTRL) as negative controls. *P < 0.05; **P < 0.01 vs. CTRL.
Fig. 5 Eﬀects of the diﬀerent compounds on production of pro-inﬂammatory
mediator tumor necrosis factor (TNF)-a: (a) monosaccharide-functionalized Glyco-
Au-NPs 1 and 2 and unbound monosaccharide 8; (b) disaccharide-functionalized
Glyco-Au-NPs 3 and 4 and unbound disaccharide 9. RAW 264.7 cells were seeded
at a density of 0.6  105 cells per well in 24-well plates and treated with
increasing concentrations (102 to 102 mM) of each compound for 24 h. TEG-
functionalized Au-NPs 5 and 6 were used as Au-NP controls while compound-
untreated cells (CTRL) as negative controls. *P < 0.05; **P < 0.01 vs. CTRL.
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View Article Online264.7 cells treated with the diﬀerent systems (1  102 mM). No
change in the expression levels of MHC II was observed in cells
treated with non-conjugated saccharides 8 and 9 or TEG-func-
tionalized Au-NPs 5 and 6, while a 3- and a 6-fold increase in the
MHC II expression was measured in cells treated with 2 or 5 nm
Glyco-Au-NPs, respectively (Table 2 and Fig. S7†). It is noteworthy
that 5 nm Glyco-Au-NPs exert identical (or even larger) MHC II
expression levels to MenA CPS. Once again, nanoparticles are
diﬀerentiated by their size and not by the presence of a mono-
meric or dimeric saccharide (or charge) on their surface.
Cellular uptake of 5 nm Glyco-Au-NPs 7 by RAW 264.7 cells
was next determined by immunouorescence and confocal
microscopy analysis. As shown in Fig. 6, uorescein-function-
alized Glyco-Au-NPs 7 are internalized (green signal) by APC
with no absorption onto the cell surface (red signal). The overall
data conrm that the Glyco-Au-NPs enter the cells and start
expressing molecules (MHC II) involved in antigen
presentation.394 | Nanoscale, 2013, 5, 390–400Glyco-Au-NPs induce T cell responses
To better explore the potentiality of these Glyco-Au-NPs as leads
for new vaccine design, their ability to induce T cell responses
was determined in human homologous monocytes/T cell co-
cultures.40 The generated T cell responses are essential for
developing a functional T cell memory following vaccination.
Thus, human monocytes were treated with increasing concen-
trations (1  102 to 1  102 mM) of each compound, and, aer
six days of cell co-cultures, T cell proliferation (Fig. 7 and S8†)
and IL-2 levels (Table 3 and Fig. S9†) were determined. Non-
conjugated saccharides 8 and 9, TEG-functionalized Au-NPs 5
and 6, as well as Glyco-Au-NPs 1 and 2 (i.e. the nanoparticles
functionalized with the monosaccharide), failed to induce
signicant T cell proliferation at all concentrations tested, while
both Glyco-Au-NPs 3 and 4 were eﬀective. Glyco-Au-NP 4 was
more potent than 3; its maximal eﬀect was a 13-fold increase at
1  101 mM in comparison with controls (native cells). Consis-
tently, the IL-2 levels in the cell culture medium (Table 3)This journal is ª The Royal Society of Chemistry 2013
Fig. 6 Laser confocal ﬂuorescence microscopy showing the intracellular localization of 5 nm ﬂuorescent Glyco-Au-NPs 7 (green) after cell treatment (3 h, panel a). In
(b) Alexa Fluor 647-conjugate anti-CD14 monoclonal antibodies (red staining) were used as surface cellular markers. Images are representative of six diﬀerent cell
preparations with similar results.
Fig. 7 Eﬀects of the diﬀerent compounds on T cell proliferation: (a) mono-
saccharide-functionalized Glyco-Au-NPs 1 and 2 and unboundmonosaccharide 8;
(b) disaccharide-functionalized Glyco-Au-NPs 3 and 4 and unbound disaccharide
9. T-cell proliferation was analyzed by FACS, and expressed as mean percentages
 SEM of proliferated T cells. Cells treated with 1 mg ml1 phytohaemagglutinin
(PHA), a widely used mitogen able to trigger cell division in T-lymphocytes, were
considered as positive controls, while TEG-functionalized Au-NPs 5 and 6 were
used as Au-NPs controls, and compound-untreated cells (CTRL) as negative
controls. *P < 0.05; **P < 0.01 vs. CTRL.
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View Article Onlinesignicantly increased aer Glyco-Au-NP 4 cell treatment
(almost a 12-fold increase at 1  101 mM vs. controls). The
overall data clearly demonstrate that Glyco-Au-NPs 4 are the
most eﬀective nanosystems in activating T cell responses.
The picture that emerges from our results is the following
(see Fig. 8a): (i) Glyco-Au-NPs activate macrophages leading to
the blockage of their cycle progression and inducing their
diﬀerentiation into dendritic-like cells; (ii) they induce on
macrophages the expression of MHC II involved in antigen
presentation to T lymphocytes; (iii) following their internaliza-
tion and degradation, the constituent saccharides are loaded
onto MHC II and are transported to the APC surface for
presentation; (iv) 5 nm Glyco-Au-NPs, functionalized with
disaccharide, signicantly induce T cell proliferation and IL-2
release. Processes (i) and (ii) require intact nanoparticles taking
advantage of their multivalency and proceed via Glyco-Au-NPs
surface recognition. Processes (iii) and (iv) involve very likely
Glyco-Au-NP degradation into APCs, a process that implies
chemical modications of the nanoparticles.
As in the case of the interaction with the antibodies,28 the
eﬃciency of the nanosystems is dependent on their size (5 nm
are better than 2 nm) but very little on the oligomerization (and
charge) of the saccharide on the surface (the eﬀect is very similar
for mono- and di-saccharide-functionalized nanoparticles,
which are neutral and anionic, respectively), see Fig. 8b. The
occurrence of a surface-recognition process controlling steps (i)
and (ii) requires a packed surface, a situation more easily
obtained with a less curved surface such as that of the larger, 5
nm, nanoparticles as compared to the smaller, 2 nm, ones. It is
interesting to point out that, in contrast, when a substrate needs
to penetrate into the organic monolayer, the opposite situation
occurs, i.e. smaller Au-NPs perform better than larger ones, as we
have recently shown.46 Processes (iii) and (iv) require nano-
particle degradation and, consistently, disaccharide-functional-
ized nanoparticles are required in this case, see Fig. 8c. Likely,
within the cell, the saccharide-functionalized thiols are detached
from the surface and, at this stage, being monomeric or dimeric
becomes relevant for T cell activation. It has been shown that theThis journal is ª The Royal Society of Chemistry 2013 Nanoscale, 2013, 5, 390–400 | 395
Table 3 Ability of the free thiols 8 and 9 and of the diﬀerent gold nanoparticles
to induce IL-2 release from activated T cells as evaluated by ELISA
Sample IL-2 releasea, pg ml1
CTRL 12  2.4
PHA 386  18b
1 14  2.2
2 19  2.3
3 16  5.1
4 144  16.6
5 15  1.3
6 13  1.4
8 18  2.1
9 13  2.2
a At a 10 mM concentration. b 1 mM.
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View Article Onlinethiolic units can be displaced from the gold surface by gluta-
thione.15,47 This mode of release utilizes the dramatic diﬀerential
between extra- and intracellular glutathione levels. It is possible
that this is what happens in this case, too. This is supported by
the increased uorescence intensity of internalized nano-
particles 7 (see Fig. 6), reasonably a consequence of the release of
the uorophore from the Au-NP surface.14 The uorescenceFig. 8 (a) Cartoon representation of the eﬀect of the Glyco-Au-NPs on macroph
monosaccharide- (circles) and disaccharide- (squares) functionalized nanoparticle eﬀ
the lines were drawn for facilitating the connection of the data points; (c) monosacch
cell proliferation (red) and IL-2 expression (blue) as a function of size; the lines wer
396 | Nanoscale, 2013, 5, 390–400intensity of uorescein when bound to the gold surface is very
small due to its quenching14 by the gold nanoparticle core while
it increases when released into the solution. In any case, T cells
appear to recognize dimeric, but not monomeric saccharide-
functionalized gold nanoparticles: whether this is due to
diﬀerences in their intracellular processing, as we suggest, or
antigenic determinants is a matter of plausible speculation and
this point should be claried in future work.
Conclusions
In conclusion, we have demonstrated that the conjugation of
small size, fully synthetic, non-immunogenic saccharides to Au-
NPs confers upon them the ability to induce immune cell
responses. The importance of multivalency to increase the
selectivity and the strength of binding but also to induce the
immunoactivity is clearly evidenced by the ineﬀectiveness of
non-conjugated saccharides, which bind to MenA antibodies
but are not immunoactive. Our data show how a complex
interplay of features is required with saccharide-functionalized
gold nanoparticles for eliciting the complex cascade of events
that induce immune responses which eventually may result in
immunization. On one hand, for maximizing the cellages and consequent T cell activation (see text for description of steps i–iv); (b)
ects on APC proliferation (blue) and MHC II expression (red) as a function of size;
aride- (circles) and disaccharide- (squares) functionalized nanoparticle eﬀects on T
e drawn for facilitating the connection of the data points.
This journal is ª The Royal Society of Chemistry 2013
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View Article Onlineinteraction, size is a key requisite, in full agreement with the
reported observation that large size nanoparticles perform
better in interacting with cell surfaces48 and mediating cell
responses.49 On the other hand, for T cell-mediated responses a
structured saccharide (in our case a disaccharide) is required. A
plausible explanation is that, at this stage, the nanosystem has
been in part degraded and the covering functional thiols have
been detached from the gold core for presentation by MHC II.
The need to comply with both requisites makes 5 nm Glyco-Au-
NPs 4 functionalized with a disaccharide the best of the studied
nanosystems for inducing immune responses in cells.
The present results may provide signicant leads for the
design of nanoparticles for developing nanoparticle-based
vaccines. The next obvious step will be to test Glyco-Au-NPs in
vivo to determine their ability to induce immunization,22 a
feasible development in view of the claimed non-toxicity of gold
nanoparticles of the size discussed here.50–53Experimental section
Synthesis of the saccharides
Synthesis of the non-conjugated saccharides 8 and 9. The non-
conjugated saccharides 8 and 9 were synthesized from their
corresponding 1-O-aminopropyl glycoside precursors as follows.
Monosaccharide 8: the aminopropyl glycoside (29 mg,
0.104 mmol) was dissolved in dry pyridine (1.0 ml) under Ar
atmosphere, and acetic anhydride (0.1 ml, 1.05 mmol); there-
aer, a catalytic amount of N,N-dimethylamino pyridine was
added. The reaction mixture was stirred at room temperature
for 3 h, and then concentrated in vacuum. The crude residue
was dissolved in dry MeOH (3.0 ml) under Ar atmosphere, and
then a 0.1M solution of MeONa in dryMeOH (0.2ml) was added
dropwise. The reactionmixture was stirred at room temperature
for 1 h, then neutralised with Dowex 50W X8 resin (H+ form),
ltered, and concentrated in vacuum. Flash chromatography
(CHCl3/MeOH 8/2) aﬀorded compound 8 (26 mg, 78%).
Disaccharide 9: the aminopropyl glycoside (20 mg,
0.034 mmol) was treated with acetic anhydride (0.038 ml,
0.34 mmol) and N,N-dimethylamino pyridine, as described for 8.
The crude residue was puried by ash chromatography (CHCl3/
MeOH from 9/1 to 7/3) providing the fully O- and N-acetylated
derivative (22 mg, 77%). This compound was dissolved in dry
MeOH (1.0 ml) under Ar atmosphere, and then a 0.1 M solution
of MeONa in dry MeOH (0.026 ml) was added. Aer stirring at
room temperature for 3 h, the reaction mixture was neutralised
with aq. HCl 5% and the solution concentrated in vacuum. The
residue was dissolved in H2O, rst eluted through a column lled
with Dowex 50W X8 resin (H+ form), and then through a column
lled with the same resin in Na+ form. The eluate was lyophilized
to aﬀord 9 (15 mg, 91%).Nanoparticle synthesis
The monomeric and dimeric saccharides used for nanoparticle
passivation as well as Glyco-Au-NPs 1–4 were synthesized as
previously described.27,28 The triethyleneglycol (TEG)-functional-
ized Au-NPs (TEG-Au-NPs) 5 and 6were synthesized as reported.36This journal is ª The Royal Society of Chemistry 2013Fluorescein-tagged GlycoNPs 7: the nanoparticles used for cell
internalization studies were prepared following the same proce-
dure, but using a mixture of two thiols, the disaccharide-func-
tionalized thiol and the uorescein-tagged thiol. The scheme for
the preparation of the Fluorescein-tagged thiol (iv, see ESI) is
reported in the ESI.† To a solution of TOABr (94 mg, 0.171 mmol)
in 68 ml toluene, an aqueous solution of HAuCl4$H2O (27 mg,
0.0685 mmol) in 1.0 ml Milli-Q water was added and shaken
vigorously until the aqueous layer became transparent. The
reddish-orange organic layer was carefully separated from the
aqueous solution and transferred in a ask with a magnetic bar.
Dioctylamine (21 mg, 0.0856 mmol) was added into the solution
under vigorous stirring at room temperature for 3 h. A solution of
NaBH4 (26 mg, 0.685 mmol) in 1.0 ml Milli-Q H2O was added
drop by drop to the organic layer under vigorous stirring (1 h).
The color of the solution immediately changed to purple. The
organic layer was again carefully separated and transferred into a
ask with a magnetic bar. The freshly prepared mixture of
disaccharide-functionalized thiol (12 mg, 0.0162 mmol) and iv
(0.70 mg, 0.0010 mmol) in DMF (1 ml) was added and allowed to
stir until the toluene layer became colorless. A red precipitate was
obtained aer centrifugation followed by decantation of the
organic layer. Aer washing with Et2O (3 30ml) and EtOAc (2
30 ml) the solid residue was dissolved with the minimum
amount of water. On slow addition of THF a red material
precipitated from the aqueous layer and the precipitate was
collected aer centrifugation followed by removal of solvents.
The same procedure was repeated to aﬀord pure 7 (17 mg).
Nanoparticle characterization
TEM images were recorded on a copper grid using a Jeol 300PX
instrument. TGA analyses were recorded by exploring a 30–800 C
interval using a temperature ramp of 20 Cmin1 under nitrogen
using a SDT 2960model TA instrument. Dynamic light scattering
(DLS) and Z potential measurements were carried out with a
Malvern Zetasizer Nano S instrument thermostatted at 25 C,
using 0.1 mg ml1 solutions of nanoparticles in water. NMR
spectra were recorded on a Bruker AC-300 or AC-250 spectrom-
eter. Diﬀusion-ordered 1H NMR spectra were recorded using the
low eddy currents distortion bipolar gradients (LEDbp) sequence,
which allows diﬀerentiation of molecules based on their diﬀu-
sion coeﬃcients. This provides not only an unequivocal conr-
mation that the thiols are bound to the Au-NPs surface, but also a
way to assess the purity of the samples. Further determinations
of the organic content of each preparation were performed both
by TGA and by analyzing the solublematerial using 1H-NMR aer
treatment with I2. Experimental results are in the ESI.†
Competitive ELISA
Ninety-six-well at-bottomed plates were incubated overnight at
4 C with a mixture of Men-A CPS (1 mg ml1) and methylated
human serum albumin (mHSA; 1 mg ml1) (Men-A CPS and
mHSA were generous gis from Novartis Farma SpA, Siena,
Italy). A solution of 5% fetal bovine serum (FBS) in phosphate
buﬀered saline (PBS) supplemented with Brij-35 (0.1%) and
sodium azide (0.05%) was added to each well to blockNanoscale, 2013, 5, 390–400 | 397
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View Article Onlineunspecic binding sites. The plates were incubated overnight at
4 C with a solution (1 : 400) of mouse anti-MenA, used as
reference serum. This serum was obtained from mice vacci-
nated with an anti-meningococcal A + C + W135 + Y poly-
saccharide vaccine. When non-conjugated saccharides 8 and 9
or Glyco-Au-NPs 1–6 were tested, they were added to each well
just before the addition of the reference serum. The plates were
then incubated with alkaline phosphatase-conjugate anti-
mouse, stained with p-nitrophenyl phosphate, and the absor-
bance was measured at 405 nm with an Ultramark microplate
reader. Experiments were repeated in triplicate. Control exper-
iments to verify unspecic binding were performed by coating
the ELISA plates with colominic acid from Escherichia coli.Cell cultures
The mouse monocyte/macrophage cell line RAW 264.7 was
cultured in high glucose Dulbecco's Modied Eagle's Medium
(DMEM) supplemented with 10% heat-inactivated FBS, 2 mM
L-glutamine, 100 U ml1 penicillin and 100 mg ml1 strepto-
mycin in a 37 C incubator with 5% CO2. Cells were grown in
75 cm2 asks and sub-cultured by scraping when they reached
90% conuence with a 1 : 5 or 1 : 10 ratio in fresh medium.
Peripheral blood mononuclear cells (PBMC) were isolated by
gradient centrifugation onto Ficoll-Hystopaque of venous blood
obtained from healthy volunteers aer their informed
consent.37 PBMC were suspended in RPMI-1640 medium con-
taining 10% heat inactivated FBS, 100 mg ml1 kanamycin,
1 mM sodium pyruvate, 2 mM L-glutamine, 1% MEM amino
acid solution and 0.01 mM 2-mercaptoethanol for immediate
use. Human monocytes were isolated from heparinised venous
blood of healthy volunteers, and their purity was assessed with
the pan-leukocyte anti-CD45 (HLE-1) and the anti-CD14 (Leu-
M3) monoclonal Abs, as previously described.37 Cells were used
on the day of isolation under endotoxin-free conditions. Before
each experiment, the viable cell count was assessed (always
>95%) by Trypan blue staining and cells were seeded, in
complete fresh medium, at diﬀerent densities 24 h prior to
compound treatments. Compound-untreated cells were
considered as negative controls, while cells treated with Men-A
(1  102 mg ml1) were considered as positive controls. Mono-
cytes and PBMC used for co-culture experiments were always
isolated from the same healthy donor.Cell proliferation
Proliferation was analyzed by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay, as previously
described.38 Briey, RAW 264.7 cells were seeded (0.5  105
cells per well) in 24-well culture plates and treated with
increasing concentrations (1  102 to 1  102 mM) of
compounds 1–8 for 24 h at 37 C in a 5% CO2 humidied
incubator. Absorbance was measured at 570–630 nm using an
Ultramark microplate reader. The percentage of cell prolifera-
tion was calculated as (x  100)/y, where x and y are the
absorbance read in compound-treated and compound-
untreated cells, respectively.398 | Nanoscale, 2013, 5, 390–400Annexin V and propidium iodide assays
The extent of apoptosis and necrosis was determined by using
annexin V-FITC and propidium iodide (PI) staining, respec-
tively. RAW 264.7 cells were seeded (1  104 cells per well) in
24-well culture plates and treated with compounds 1–8 (1 
102 mM) for 24 h at 37 C in a 5% CO2 humidied incubator.
Aer treatment with test compounds, culture media were
removed, cells washed twice with annexin binding buﬀer (10
mMHepes sodium salt, 150 mM NaCl, 5 mM KCl, 1 mMMgCl2,
1.8 mM CaCl2, pH 7.4), and incubated in binding buﬀer con-
taining annexin V-FITC (1 mg ml1) and PI (20 mg ml1) for
15 min at 37 C in the dark. Aer two washes with binding
buﬀer, cells were analyzed under epiuorescence microscopy.
For each sample, apoptotic and necrotic cells were counted in
six random high-power elds. The relative apoptotic and
necrotic cells were expressed as the percentage of the total cells
in each sample. Actinomycin D (0.5 mg ml1) was included as a
positive control of apoptosis.Macrophage morphology assessment
RAW 264.7 cells were seeded (1  105 cells per well) in 6-well
culture plates and treated with compounds 1–8 (1  102 mg
ml1) for 24 h at 37 C in a 5% CO2 humidied incubator.
Following incubation, cells were washed once with PBS and
analyzed under optical microscope. Six diﬀerent elds were
observed for control cells (CTRL; compound-un-treated cells),
as well as for cells treated with diﬀerent compounds (1–6 and 8,
9), and used for counting cells with normal or dendritic-like
morphology. Cells with dendritic-like morphology in the view
eld were calculated as the percentage of all cells observed.Production of reactive oxygen species
Intracellular reactive oxygen species production was measured
by incubating the cells with the uorescent probe 20,70-
dichlorodihydrouorescein diacetate (DCFH-DA), as previously
described.54 RAW 264.7 cells were seeded (0.5  105 cells per
well) in 24-well plates and treated with increasing concentra-
tions (102 to 102 mM) of each compound for 1 h. Accumulation
of dichlorouorescein was measured as an increase in the
uorescence at 525 nm, when the samples were excited at 488
nm using a microplate spectrouorometer.Production of TNF-a
Compounds were tested for their eﬀects on the production of
pro-inammatory mediators, such as tumor necrosis factor
(TNF)-a, as previously described.54 RAW 264.7 cells were seeded
at a density of 0.6  105 cells per well in 24-well plates and
treated with increasing concentrations (102 to 102 mM) of each
compound for 24 h. At the end of each experiment, superna-
tants were collected and stored until measurements.
The amounts of TNF-a in cell culture medium were assayed
using enzyme-linked immunosorbent assay (ELISA). The
concentrations of the cytokine in the samples were determined
by extrapolation from specic reference standard curves.This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineGlyco-Au-NP uptake by macrophages
The cellular uptake of 5 nm Glyco-Au-NPs was assessed
analyzing intracellular localization of FITC-labeled 5 nm Glyco-
Au-NPs (14) by confocal scanning laser microscopy. RAW 264.7
cells (1  104 cells per well) were allowed to adhere overnight on
sterile cover slips in 24-well culture plates and pulsed (3 h) with
(1  102 mg ml1) FITC-labeled 5 nm Glyco-Au-NPs in complete
medium. The cover slips were washed twice with ice-cold PBS
and cells xed with paraformaldehyde 3% for 15 min at 4 C.
Aer two additional PBS washings, cell membranes on the cover
slips were labelled with ALexa Fluor 647-conjugated anti-mouse
CD14 monoclonal Ab at room temperature for 1 h in the dark.
Aer one wash with PBS, the cover slips were mounted on glass
slides by SlowFade reagent. Cover slips were maintained in the
dark overnight at 4 C and analyzed by a confocal scanning laser
microscope (Leica TCS P2). Green uorescence was observed
with a 505–550 nm band-pass emission lter under 488 nm laser
illumination and red uorescence was observed with a 560 nm
long-pass emission lter under 543 nm laser illuminations.Flow cytometry analysis
The acquisition of eﬀector functions by macrophages was
assessed analyzing the levels of major histocompatibility
complex class II (MHC II) surface expression. RAW 264.7 cells
were seeded (1  105 cells per well) in 6-well culture plates and
treated with compounds 1–8 (1  102 mM) for 24 h at 37 C in a
5% CO2 humidied incubator. Following incubation, cells were
washed once with PBS, resuspended in 100 ml PBS and incu-
bated with Alexa Fluor 647-conjugated anti-mouse I-A/I-E
monoclonal Ab for 15 min at room temperature in the dark.
Cells were then washed twice with PBS and analyzed by ow
cytometry. Emitted uorescence was analyzed by using FACS-
Diva soware.T cell activation assays
Monocytes (1  105 cells per well), used as APCs, were pulsed
with increasing concentrations (1 102 to 1  102 mM) of each
compound 1–8 for 24 h. Responder PBMC (1  106 cells per ml)
were labeled with 0.25 mM carboxyuorescein succinimidyl
ester (CFSE) in serum-free PBS for 30 min at 37 C. Filtered FBS
was then added to stop the reaction, and cells were washed
several times with RPMI-1640. 5  104 CFSE-labeled responder
T cells were co-cultured with antigen-pulsed or unpulsed
homologous monocytes for six days at 37 C, 5% CO2 in a
humidied incubator. Phytohemagglutinin (PHA) (1 mg ml1)
was used as a positive control of PBMC proliferation. Aer six
days of co-culture, cells were harvested, washed three times with
warmed PBS, resuspended in fresh PBS, and analyzed by ow
cytometry. Cell proliferation was measured as reduction of
CFSE uorescence intensity due to cell division by using
FACSDiva soware.Measurement of IL-2 production
Monocytes (1  105 cells per well), used as APCs, were pulsed
with increasing concentrations (1  102 to 1  102 mM) ofThis journal is ª The Royal Society of Chemistry 2013compounds 1–8 for 24 h. Responder PBMC (5  104 cells per
well) were co-cultured with antigen-pulsed or unpulsed
homologous monocytes for six days at 37 C, 5% CO2 in a
humidied incubator. PHA (1 mg ml1) was added in positive
control wells. Aer six days of co-culture, the supernatants were
collected and stored at 20 C until assays. The levels of IL-2
were measured by ELISA using a mouse anti-human IL-2
monoclonal Ab and quantied with a recombinant IL-2 stan-
dard. Absorbance was measured at 450 nm using an Ultramark
microplate reader, and the concentration of IL-2 in each sample
was determined by extrapolation from reference standard
curves. The detection limit of this method was 4 pg ml1.
Statistical analysis
Results are expressed as means  SEM of at least ve diﬀerent
experiments run in triplicate. Statistical signicance was eval-
uated by Student's t-test for unpaired varieties. Diﬀerences were
considered statistically signicant when p < 0.05. The soware
Origin version 6.0 (Microcal Soware) was used as a nonlinear
regression model for analysis of the concentration–response
data to obtain the 50% inhibitory concentration value (IC50).
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